O1385

Ozagrel hydrochloride hydrate

≥98% (HPLC), solid

• Synonyme(s) : (E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic acid hydrochloride hydrate, OKY-046
• Formule empirique (notation de Hill) : C₁₃H₁₂N₂O₂ · HCl · xH₂O
• CAS Number: 78712-43-3
• Poids moléculaire : 264.71 (anhydrous basis)
• Numéro MDL: MFCD00911569
• Code UNSPSC : 12352200
• ID de substance PubChem : 24897942
• Nomenclature NACRES : NA.77

Propriétés

• Niveau de qualité: 100
• Essai: ≥98% (HPLC)
• Forme: solid
• Conditions de stockage: desiccated
• Couleur: white to off-white
• Solubilité: H₂O: soluble
• Température de stockage: room temp
• Chaîne SMILES: O.Cl.OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1
• InChI: 1S/C13H12N2O2.ClH.H2O/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;;/h1-8,10H,9H2,(H,16,17);1H;1H2/b6-5+;;
• Clé InChI: OWIZTYOMGVTSDP-TXOOBNKBSA-N

Description

Application

Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor:

• in high cholesterol-diet rats (HC) to test its effect on arteriolar constriction
• to pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changes
• to test its effect on arteriolar vasoconstriction in hyperglycemic mice

Actions biochimiques/physiologiques

Ozagrel is a selective thromboxane A₂ synthase (TXA₂) inhibitor.

Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation. Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2) in the acute phase of cerebral ischemia. It improves endothelial dysfunction in L-methionine-induced hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID).

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 2
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable
• Équipement de protection individuelle: Eyeshields, Gloves, type N95 (US)